Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Breast Cancer | Research article

Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines

Authors: Juraimi Raihan, Umar Ahmad, Yoke Keong Yong, Zolkapli Eshak, Fauziah Othman, Aini Ideris

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Different strains of Newcastle disease virus (NDV) worldwide proved to have tumouricidal activity in several types of cancer cells. However, the possible anti-cancer activity of Malaysian NDV AF2240 strain and its mechanism of action remains unknown. The ability of cytokine-related apoptosis-inducing NDV AF2240 to treat breast cancer was investigated in the current study.

Methods

A total of 90 mice were used and divided into 15 groups, each group comprising of 6 mice. Tumour, body weight and mortality of the mice were determined throughout the experiment, to observe the effect of NDV and NDV + tamoxifen treatments on the mice. In addition, the toxic effect of the treatments was determined through liver function test. In order to elucidate the involvement of cytokine production induced by NDV, a total of six cytokines, i.e. IL-6, IFN-γ, MCP-1, IL-10, IL12p70 and TNF-α were measured using cytometric bead array assay (plasma) and enzyme-linked immunosorbent spot (isolated splenocytes).

Results

The results demonstrated that 4 T1 breast cancer cells in allotransplanted mice treated with AF2240 showed a noticeable inhibition of tumour growth and induce apoptotic-related cytokines.

Conclusions

NDV AF2240 suppression of breast tumour growth is associated with induction of apoptotic-related cytokines. It would be important to further investigate the molecular mechanism underlaying cytokines production by Newcastle disease virus.
Appendix
Available only for authorised users
Literature
1.
Omar ZA, NSI T. National Cancer Registry Report 2007. In: Malaysia Cancer Statistics-Data and Figure. Kuala Lumpur: National Cancer Registry, Ministry of Health Malaysia; 2011. p. 89.
2.
Azizah AM, Nor Saleha IT, Noor Hashima A, Asmah ZA, Mastulu W. Malaysian National Cancer Registry Report 2007–2011. Malaysia Cancer Statistics – Data and Figure 2007. Malaysia cancer statistics, data and figure. Putrajaya: National Cancer Institute, Ministry of Health; 2016
3.
Yip CH, Taib NA, Mohamed I. Epidemiology of breast cancer in Malaysia. Asian Pac J Cancer Prev. 2006;7(3):369–74.PubMed
4.
Jordon V. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993;110(2):507–17.CrossRef
5.
Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309–18.PubMedCrossRef
6.
Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist. 2004;9:43–9.PubMedCrossRef
7.
Bender CMSS, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14(6):995–8.PubMedPubMedCentralCrossRef
8.
Grilli S. Tamoxifen (TAM): the dispute goes on. Ann 1st Super Sanita. 2006;42(2):170–3.
9.
Stojdl DFLB, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6(7):821–5.PubMedCrossRef
10.
Heise CHT, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6(10):1134–9.PubMedCrossRef
11.
Parato KASD, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005;5(12):965–76.PubMedCrossRef
12.
Markert JMMM, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7(10):867–74.PubMedCrossRef
13.
Myers RGS, Harvey M, Soeffker D, Frenzke M, Abraham K, Shaw A, Rozenblatt S, Federspiel MJ, Russell SJ, Peng KW. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 2005;12(7):593–9.PubMedCrossRef
14.
Unno YSY, Kondo F, Igarashi N, Wang G, Shimura R, Yamaguchi T, Asano T, Saisho H, Sekiya S, Shirasawa H. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin Cancer Res. 2005;11(12):4553–60.PubMedCrossRef
15.
Zamarin D, Palese P. Oncolytic Newcastle Disease Virus for. Cancer Therapy. 2012:25–30.
16.
Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol. 2002;21(1):85–93.PubMed
17.
Alexander DJ SD: Newcastle disease, other avian paramyxoviruses and pneumovirus infection. In: Disease of Poultry. 12 edn. Edited by YM S: Ames: Iowa State University Press; 2008: 75–100.
18.
Park MS, García-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol. 2003;77(17):9522–32.PubMedPubMedCentralCrossRef
19.
Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol. 2010;84(8):3835–44.PubMedPubMedCentralCrossRef
20.
Meyyappan N. Effect Of Newcastle Disease Virus On The Mcf-7 And Mda-Mb-231 Breast Cancer Cell Lines Universiti Putra Malaysia; 2003.
21.
Fauziah OOA, Patimah I, Aini I. Microscopic evaluation of Newcastle disease virus (NDV) a killer in chicken but a possible live saver in human. J Elect Micro Soc Thailand. 2002;16:272.
22.
Coughlin CMSK, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WM. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest. 1998;101(6):1441–52.PubMedPubMedCentralCrossRef
23.
Yurchenko KS, Zhou P, Kovner AV, Zavjalov EL, Shestopalova LV, Shestopalov AM. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS One. 2018;13(4):e0195425.PubMedPubMedCentralCrossRef
24.
Yaacov B, Eliahoo E, Elihaoo E, Lazar I, Ben-Shlomo M, Greenbaum I, Panet A, Zakay-Rones Z. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. 2008;15(12):795–807.PubMedCrossRef
25.
Mazija H, Cajavec S, Ergotic N, Ciglar-Grozdanic I, Gottstein Z, Ragland WL. Immunogenicity and safety of Queensland V4 and Ulster 2C strains of Newcastle disease virus given to maternally immune, newly hatched chickens by nebulization. Avian Dis. 2010;54(1):99–103.PubMedCrossRef
26.
Alabsi AM, Ali R, Ideris A, Omar AR, Bejo MH, Yusoff K, Ali AM. Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo. Leuk Res. 2012;36(5):634–45.PubMedCrossRef
27.
Othman FAIGMEAR. Oncolytic effect of Newcastle disease virus AF2240 strain on the MCF-7 breast cancer cell line. Yakhteh Med J. 2010;12:17–24.
28.
Zamarin D, Palese P: Oncolytic Newcastle Disease Virus for Cancer Therapy Mechanisms of NDV-mediated Oncolysis. 2013, 7(3):347–367.
29.
Meyyapan N: Oncolytic Effect of Newcasle Disease Virus on te MCF-7 and MDA-MB-231 Breast Cancer Cell Lines. Master. Universiti Putra Library: Universiti Putra Malaysia; 2003.
30.
Anushia S: Effect of Newcastle Disease Virus AF2240 on Allografted 4T1 Breast Cancer Cells in BALB/c Mice. Master. Universiti Putra Library: Universiti Putra Malaysia; 2010.
31.
Blaskovic DSB. Laboratory methods of virus transmission in multicellular organisms. Virology. 1967;1:163–233.
32.
Yusoff K, Tan WS. Newcastle disease virus: macromolecules and opportunities. Avian Pathol. 2001;30(5):439–55.PubMedCrossRef
33.
DJ Alexander: Newcastle disease diagnosis. In: Newcastle Disease. edn. Edited by DJ A. Boston, Dordrecht, London: Kluwer Academic Publishers; 1998: 147–160.CrossRef
34.
Yang R, Pei X, Wang J, Zhang Z, Zhao H, Li Q, Zhao M, Li Y. Protective effect of a marine oligopeptide preparation from chum salmon (Oncorhynchus keta) on radiation-induced immune suppression in mice. J Sci Food Agric. 2010;90(13):2241–8.PubMedCrossRef
35.
Argmann CA, Auwerx J: Collection of blood and plasma from the mouse. Curr Protoc Mol Biol 2006, Chapter 29:Unit 29A 23.
36.
Abschuetz A, Kehl T, Geibig R: Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells. Cell and tissue … 2006.
37.
Angelova AL, Aprahamian M, Balboni G, Delecluse H-J, Feederle R, Kiprianova I, Grekova SP, Galabov AS, Witzens-harig M, Ho AD, et al. Oncolytic Rat Parvovirus H-1PV , a Candidate for the Treatment of Human Lymphoma : In Vitro and In Vivo Studies. Nature. 2009;17(7):1164–72.
38.
39.
Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol. 2006;80(15):7522–34.PubMedPubMedCentralCrossRef
40.
Ahmed I, Ahmad U, Keong Y, Manna N, Othman F. Induction of Nitric Oxide and TNF-Α in Newcastle Disease Virus (NDV) AF2240 Infected RAW 264.7 Macrophages and their Cytotoxic Activity on MDA-MB-231 Breast Cancer Cell Line. J Cancer Sci Ther. 2014;6:478–82.
41.
Hrabák A, Csuka I, Bajor T, Csatáry LK. The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro. Cancer Lett. 2006;231(2):279–89.PubMedCrossRef
42.
Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20(9):2251–66.PubMedCrossRef
43.
Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006;13(1):221–8.PubMedCrossRef
44.
Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001;172(1):27–36.PubMedCrossRef
45.
Zulkifli MM, Ibrahim R, Ali AM, Aini I, Jaafar H, Hilda SS, Alitheen NB, Abdullah JM. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma. Neurol Res. 2009;31(1):3–10.PubMedCrossRef
46.
Alabsi AM, Bakar SAA, Ali R, Omar AR, Bejo MH, Ideris A, Ali AM. Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines. Int J Mol Sci. 2011;12(2011):8645–60.PubMedPubMedCentralCrossRef
47.
Ahmad U, Ahmed I, Keong YY, Abd Manan N, Othman F. Inhibitory and apoptosis-inducing effects of newcastle disease virus strain AF2240 on mammary carcinoma cell line. Biomed Res Int. 2015;2015.
48.
Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomark Prev. 2005;14(3):656–61.CrossRef
49.
Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20(4):1128–43.PubMedCrossRef
50.
Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan Afr Med J. 2009;3:17.PubMedPubMedCentral
51.
Rahman MF, Siddiqui MK, Jamil K. Effects of Vepacide (Azadirachta indica) on aspartate and alanine aminotransferase profiles in a subchronic study with rats. Hum Exp Toxicol. 2001;20(5):243–9.PubMedCrossRef
52.
Parvez S, Tabassum H, Rehman H, Banerjee BD, Athar M, Raisuddin S. Catechin prevents tamoxifen-induced oxidative stress and biochemical perturbations in mice. Toxicology. 2006;225(2–3):109–18.PubMedCrossRef
53.
Elefsiniotis ISPK, Ilias A, Pallis L, Mariolis A, Glynou I, Kada H, Moulakakis A. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol. 2004;16(6):593–8.PubMedCrossRef
54.
Nyblom H, Björnsson E, Simrén M, Aldenborg F, Almer S, Olsson R. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int. 2006;26(7):840–5.PubMedCrossRef
55.
Huang SS, Huang PH, Leu HB, Wu TC, Lin SJ, Chen JW. Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome X. Heart. 2010;96(15):1227–32.PubMedCrossRef
56.
Rios DL, Cerqueira CC, Bonfim-Silva R, Araújo LJ, Pereira JF, Gadelha SR, Barbosa AA. Interleukin-1 beta and interleukin-6 gene polymorphism associations with angiographically assessed coronary artery disease in Brazilians. Cytokine. 2010;50(3):292–6.PubMedCrossRef
57.
Mitsuyama K, Sata M, Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev. 2006;17(6):451–61.PubMedCrossRef
58.
Zhang Y, Hayes A, Pritchard A, Thaker U, Haque MS, Lemmon H, Harris J, Cumming A, Lambert JC, Chartier-Harlin MC, St Clair D, Iwatsubo T, Mann DM, Lendon CL. Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. Neurosci Lett. 2004;362(2):99–102.PubMedCrossRef
59.
Esfandi F, Ghobadloo SM, Basati G. Interleukin-6 level in patients with colorectal cancer. Cancer Lett. 2006;244(1):76–8.PubMedCrossRef
60.
Dowlati A, Levitan N, Remick SC. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J Lab Clin Med. 1999;134(4):405–9.PubMedCrossRef
61.
Soygur H, Palaoglu O, Akarsu ES, Cankurtaran ES, Ozalp E, Turhan L, Ayhan IH. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(6):1242–7.CrossRef
62.
Hodge DR, Xiao W, Wang LH, Li D, Farrar WL. Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol Ther. 2004;3(2):188–94.PubMedCrossRef
63.
Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20(42):5991–6000.PubMedCrossRef
64.
Lorence RM, Rood PA, Kelley KW. Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor-α and Augmentation of Its Cytotoxicity. J Natl Cancer Inst. 1988;80(16):1305–12.PubMedCrossRef
65.
Rood PA, Lorence RM, Kelley KW. Serum Protease Inhibitor Abrogation of Newcastle Disease Virus Enhancement of Cytolysis by Recombinant Tumor Necrosis Factors Alpha and Beta. J Natl Cancer Inst. 1990;82(3):213–7.PubMedCrossRef
66.
Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V, Walczak H. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol. 2003;170(4):1814–21.PubMedCrossRef
67.
Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4(7):429–37.PubMedCrossRef
68.
Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996;87(9):3877–82.PubMed
69.
Dias S, Thomas H, Balkwill F. Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer. 1998;75(1):151–7.PubMedCrossRef
70.
HD NCLE, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994;153(4):1697–706.
71.
Elgert KD. Immunology: Understanding the immune system. 2nd ed. New Jersey: Wiley; 2009.
72.
Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997;71(4):630–7.PubMedCrossRef
73.
Piancatelli D, Romano P, Sebastiani P, Adorno D, Casciani CU. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother. 1999;22(1):25–32.PubMedCrossRef
74.
Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.PubMedCrossRef
75.
Hatanaka H, Abe Y, Naruke M, Tokunaga T, Oshika Y, Kawakami T, Osada H, Nagata J, Kamochi J, Tsuchida T, Kijima H, Yamazaki H, Inoue H, Ueyama Y, Nakamura M. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. Clin Cancer Res. 2001;7(5):1287–92.PubMed
76.
Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P, Langsenlehner U. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat. 2010;119(3):701–5.PubMedCrossRef
77.
Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82–4.PubMed
78.
Razmkhah M, Jaberipour M, Erfani N, Habibagahi M, Talei AR, Ghaderi A. Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response? Cell Immunol. 2011;266(2):116–22.PubMedCrossRef
79.
Toi M, Harris AL, Bicknell R. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun. 1991;174(3):1287–93.PubMedCrossRef
80.
Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6(8):3282–9.PubMed
81.
Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, Koelbl H. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004;25(1–2):14–7.PubMedCrossRef
82.
Conti P, DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc. t2001;22(3):133–7.PubMedCrossRef
Metadata
Title
Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines
Authors
Juraimi Raihan
Umar Ahmad
Yoke Keong Yong
Zolkapli Eshak
Fauziah Othman
Aini Ideris
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5516-5

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer

Research article

Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data

Research article

Estimation of immune cell content in tumor using single-cell RNA-seq reference data

Research article

Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma

Research article

The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer

Research article

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits